Descripción de la empresa
Longeveron Inc. operates as a clinical stage biotechnology entity focused on developing cellular therapies designed to address aging-related conditions and life-threatening diseases within the United States market. The company functions within the broader healthcare sector, specifically targeting the specialized industry of biotechnology, which implies a high-risk, high-reward environment reliant on successful clinical trials and regulatory approvals. In terms of scale, the firm currently maintains a market capitalization of $33.97M, generates annual revenue of $1.20M, and employs a workforce of 38 individuals. These financial metrics indicate that Longeveron is a micro-cap entity with a relatively small revenue base, suggesting it is in an early-stage development phase where the value is primarily derived from intellectual property and potential future product launches rather than established commercial sales streams.
Salud financiera
The company reported a revenue of $1.20M over the trailing twelve months, while simultaneously posting a net income of $-22,704,000 and an EBITDA of $-22,061,000. The significant disparity between the modest revenue figure and the substantial net loss reveals a cost structure dominated by heavy research and development expenditures and operational burn rates typical of pre-commercial biotechnology firms. Free cash flow stands at $-11,171,375, which indicates that the company is currently consuming cash reserves to fund its operations and clinical programs, thereby limiting its immediate financial flexibility for external expansion without additional capital raises. The gross margin is reported at 67.0%, suggesting efficient production costs relative to sales, whereas the operating margin is a negative 1479.2% and the profit margin is 0.0%, reflecting the intense unprofitability inherent in the company's current business model before achieving commercial scale. On the balance sheet, the company holds $4.66M in cash against $824,000 in debt, resulting in a debt-to-equity ratio of 14.52. Despite the low absolute debt level, the high debt-to-equity ratio technically classifies the capital structure as leveraged, though the debt burden remains manageable relative to available cash liquidity. The current ratio of 1.33 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a baseline level of liquidity stability. Furthermore, the return on equity is -164.7% and the return on assets is -81.3%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or creditors due to the ongoing nature of the clinical stage operations.
Evaluación de valoración
Longeveron Inc. does not have a trailing P/E ratio available, while the forward P/E is listed as -0.76, implying that earnings are negative and traditional price-to-earnings valuation models are not applicable for this stage of the company. The price-to-book ratio is 4.70, which indicates that the market is pricing the company at a significant premium over its book value, likely reflecting high expectations regarding the potential success of its lead investigational product, LOMECEL-B. The price-to-sales ratio is 28.33 and the EV/EBITDA is -1.05, suggesting that investors are valuing the firm based on revenue potential and asset quality rather than current profitability or cash generation capabilities. The stock's 52-week high is $1.83 and the 52-week low is $0.47, meaning the current price sits somewhere within this wide trading range, exhibiting significant volatility relative to its recent price history. The beta value is -0.19, an unusual negative figure that suggests the stock's price movements have historically moved in the opposite direction of the broader market or displayed a distinct lack of correlation, indicating highly idiosyncratic risk factors rather than standard market beta exposure.
Growth & Income
The company experienced a revenue growth rate of -39.5% year over year, while the earnings growth rate is N/A due to the lack of profitability; consequently, earnings are not growing faster than revenue because both are contracting or negative. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available earnings, however negative, are not being distributed to shareholders but are instead retained for reinvestment into clinical trials and growth initiatives. Since the firm does not pay dividends, the strategy focuses entirely on allocating capital resources toward the development of cellular therapies rather than providing income distributions to investors. The overall growth and income profile for Longeveron Inc. is characterized by negative revenue contraction, a complete absence of dividend income, and a reliance on capital markets to sustain operations in the absence of positive cash flow generation.